Status:
COMPLETED
Reinforcement Learning in Diabetes Mellitus Trial
Lead Sponsor:
Brigham and Women's Hospital
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Diabetes Mellitus, Type 2
Medication Adherence
Eligibility:
All Genders
18-84 years
Phase:
NA
Brief Summary
Reinforcement learning is an advanced analytic method that discovers each individual's pattern of responsiveness by observing their actions and then implements a personalized strategy to optimize indi...
Detailed Description
The goal of this pilot study is to develop and test a novel reinforcement learning-enhanced text messaging program to support medication adherence in patients with type 2 diabetes. This pilot study wi...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Age between 18-84 years
- Diagnosed with type 2 diabetes mellitus (T2DM) and are prescribed between 1-3 daily oral medications for this disease
- Currently have a smartphone with a data plan or WiFi at home
- HbA1c level ≥7.5%
- Basic working knowledge of English
- Willing and able to set up the platform and adhere to study procedures
- Either not currently using a pillbox or willing to use electronic pill bottles (EDMs) for diabetes medications for the duration of the study
- Exclusion criteria:
- Patients with active enrollment in another diabetes trial within Mass General Brigham
- Patients who receive daily assistance with taking their medications at home
- Patients who are unable to receive text messages for more than 3 days in a row during the study period
Exclusion
Key Trial Info
Start Date :
February 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 28 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04473326
Start Date
February 4 2021
End Date
January 28 2022
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02120